Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Comment by wildbird1on Mar 19, 2023 9:27am
345 Views
Post# 35347430

RE:About the addition of up to 9 CSS ...

RE:About the addition of up to 9 CSS ...Eoganacht nice article....In the link that you provided, a team of scientists did use TLD-1433(provided by TLT) to find a possible treatment for Conjunctival Melanomia.

1) Conjunctival Melanomia is a rare but often deadly ocular cancer(it is increasing worldwide).

2) There is no FDA-approved systemic treatment for Conjunctival Melanomia, it is an incurable cancer.

3) In the article, after testing TLD-1433, the scientific team concluded that, " Based on our results, we suggest repurposing of TLD-1433 for treatment of incurable Conjunctival Melanomia, and further testing in alternative pre-clinical models".

Wow..! TLD-1433 has not yet been approved by the FDA for Bladder cancer, and scientists are already finding ways to use it on some incurable cancer.

You have to like the future potential of TLT-PDT.



<< Previous
Bullboard Posts
Next >>